SS
PBMWW

Steve Schonfeld’s Psyence Biomedical Warrant PBMWW Stock Holding History

Steve Schonfeld’s Portfolio PBMWW Stock Details PBMWW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,300
Closed -$1.7K – 2617
2024
Q1 		$1.7K Buy
+24,300
New +$1.51K ﹤0.01% 1971

Other funds holding PBMWW

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Steve Schonfeld's PBMWW Position: Q2 2024 in Review

Steve Schonfeld sold out of Psyence Biomedical Warrant (PBMWW) in Q2 2024, closing a stake of 24,300 shares — an estimated $1.7K sold.

Steve Schonfeld first reported a position in PBMWW in Q1 2024 and held it in 1 quarter. The position peaked at $1.7K in Q1 2024. 28 funds tracked by Wall St. Rank hold PBMWW as of Q2 2024.

  • Steve Schonfeld reported no remaining Psyence Biomedical Warrant position as of Q2 2024 after selling out during the quarter.
  • Steve Schonfeld sold 24,300 Psyence Biomedical Warrant shares in Q2 2024, an estimated $1.7K.
  • Steve Schonfeld first reported a position in Psyence Biomedical Warrant in Q1 2024 and held it in 1 quarter.
  • Steve Schonfeld's Psyence Biomedical Warrant position peaked at $1.7K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Psyence Biomedical Warrant as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.